Cargando…

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

Immunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines. Dengue, caused by a mosquito-transmitted flavivirus endemic to many tropical and su...

Descripción completa

Detalles Bibliográficos
Autores principales:	LeFevre, Inge, Bravo, Lulu, Folschweiller, Nicolas, Medina, Eduardo Lopez, Moreira, Edson Duarte, Nordio, Francesco, Sharma, Mayuri, Tharenos, Leslie M., Tricou, Vianney, Watanaveeradej, Veerachai, Winkle, Peter J., Biswal, Shibadas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208910/ https://www.ncbi.nlm.nih.gov/pubmed/37230978 http://dx.doi.org/10.1038/s41541-023-00670-6

Ejemplares similares

97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View
por: Tricou, Vianney, et al.
Publicado: (2021)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)
por: Rivera, Luis, et al.
Publicado: (2021)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023)

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination
por: López-Medina, Eduardo, et al.
Publicado: (2020)

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study
por: Tricou, Vianney, et al.
Publicado: (2023)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate
por: Patel, Sanjay S, et al.
Publicado: (2022)

Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial
por: Turner, Mark, et al.
Publicado: (2020)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
por: Whitehead, Stephen S., et al.
Publicado: (2017)

Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
por: Moris, Philippe, et al.
Publicado: (2019)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
por: Waickman, Adam T., et al.
Publicado: (2019)

Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
por: El Helou, Guy, et al.
Publicado: (2020)

Clinical epidemiology, risk factors and treatment outcomes of extended-spectrum beta-lactamase producing Enterobacteriaceae bacteremia among children in a Tertiary Care Hospital, Bangkok, Thailand
por: Nivesvivat, Thirapa, et al.
Publicado: (2018)

Immunogenicity of a novel tetravalent dengue envelope protein domain III-based antigen in mice
por: Fahimi, Hossein, et al.
Publicado: (2018)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth
por: Moyo, Nathifa, et al.
Publicado: (2020)

Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
por: Hannawi, Suad, et al.
Publicado: (2023)

Safety of Dengue Vaccine?
por: Biswal, Shibadas, et al.
Publicado: (2022)

Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil
por: Dayan, Gustavo H., et al.
Publicado: (2013)

Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
por: Kirstein, Judith, et al.
Publicado: (2018)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial
por: Watanaveeradej, Veerachai, et al.
Publicado: (2014)

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children
por: Cha, Sung-Ho, et al.
Publicado: (2014)

Development and evaluation of a tetravalent botulinum vaccine
por: Shi, Dan-Yang, et al.
Publicado: (2022)

Top Physics at ATLAS 003
por: Stavropoulos, G D
Publicado: (2004)

Transplacental Chikungunya Virus Antibody Kinetics, Thailand
por: Watanaveeradej, Veerachai, et al.
Publicado: (2006)

Complete Genome Sequence of a Rabies Virus Isolated from a Human in Central African Republic
por: Tricou, Vianney, et al.
Publicado: (2014)

Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone
Publicado: (1996)

Enantiomerically Pure Tetravalent Neptunium Amidinates: Synthesis and Characterization
por: Fichter, Sebastian, et al.
Publicado: (2020)

Bonding Trends in Tetravalent Th–Pu Monosalen Complexes
por: Radoske, Thomas, et al.
Publicado: (2020)

Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial
por: Dubey, Anand Prakash, et al.
Publicado: (2015)

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial
por: Danko, Janine R., et al.
Publicado: (2018)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_05anla2r83ghmh3iqq0v7snova